말레이시아의 경구 항당뇨병제 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the Malaysia oral anti-diabetic drug market size is expected to grow from USD 282.22 million in 2025 to USD 290.46 million in 2026 and is forecast to reach USD 335.47 million by 2031 at 2.92% CAGR over 2026-2031.

This report is Segmented by Drug Class (Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones, Alpha-Glucosidase Inhibitors, and More), Age Group (Adults, Pediatric, Geriatric), Diabetes Type (Type 1 Diabetes, Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

Malaysia Oral Anti-Diabetic Drug Market Trends and Insights

Escalating Prevalence of Type-2 Diabetes in Urban Malaysia

Urban centres now post diabetes prevalence of 19.6 deaths per 100,000 population, placing the disease among Malaysia's top mortality drivers. Registry data spanning a decade lists 288,913 diagnosed patients, and only one-third meet lipid and blood-pressure targets, indicating wide therapeutic gaps . Sedentary lifestyles and nutrition shifts compound genetic predisposition, so pharmacotherapy remains essential even as prevention programs expand. Public hospitals respond by stockpiling metformin and by trialling fixed-dose combinations in primary care. This unmet need anchors baseline growth for the Malaysia oral anti-diabetic drug market.

Expansion of the Private Health-Insurance Pool

Healthcare spending reached 4.38% of GDP in 2025, with private insurance uptake rising among middle-income households. Broader coverage lowers out-of-pocket costs for premium agents such as SGLT-2 and DPP-4 inhibitors. Employer schemes in Kuala Lumpur, Selangor, and Penang now reimburse combination tablets that previously strained household budgets. New policies for foreign workers widen the risk pool and lift unit volumes. Insurers, in turn, negotiate tiered pricing with manufacturers, reinforcing value-based payment models in the Malaysia oral anti-diabetic drug market.

Intensifying Generic Competition After Key Patent Expiries

Empagliflozin's patent expiry in March 2025 and scheduled sitagliptin/metformin expiries in 2029 invite generic entries priced 50% lower in line with national policy. Indian firms have publicly targeted off-patent launches, and local manufacturers seek fast-track approvals under the updated NPRA guidebook. Branded incumbents respond with patient-support programs and fixed-dose lifecycle extensions. Volume may rise, yet value erosion weighs on headline growth for the Malaysia oral anti-diabetic drug market.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Uptake of SGLT-2 & DPP-4 Inhibitors Post-NEML 2024 Update
2. Government-Led "Mysihat" Medication-Adherence Programmes
3. High Out-of-Pocket Cost for Latest Agents Despite Reimbursement

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Biguanides retained 37.72% of the Malaysia oral anti-diabetic drug market share in 2025 owing to metformin's entrenched role as first-line therapy. SGLT-2 inhibitors contribute small base revenues but grow at 3.45% CAGR, lifted by cardiovascular and renal outcome data. Sulfonylurea sales trend downward because of hypoglycaemia concerns, while DPP-4 inhibitors stabilise as second-line options in elderly cohorts. Alpha-glucosidase inhibitors and thiazolidinediones stay niche after gastrointestinal and safety drawbacks.

Fixed-dose combinations pairing metformin with SGLT-2 or DPP-4 molecules broaden adherence and command premium pricing. Upcoming generic metformin entries cushion price declines within the Malaysia oral anti-diabetic drug market. Meanwhile, exclusivity on newer classes allows innovators to recoup R&D spend. Manufacturers emphasise post-marketing surveillance to reassure prescribers on rare renal adverse events linked to SGLT-2 therapy.

Adults aged 20-65 years generated 66.58% of revenue in 2025, reflecting Malaysia's primary working-age population base. The geriatric cohort, however, is set to expand at a 3.78% CAGR through 2031 as longevity improves and screening intensity rises. Paediatric cases remain minor but escalate with urban childhood obesity.

Geriatric prescribing patterns tilt to DPP-4 inhibitors for low hypoglycaemia risk, while adults receive broader regimens including SGLT-2 tablets. Rural outreach programs in Sarawak now offer quarterly medication reviews for seniors, lifting adherence. As comorbid conditions accumulate, demand shifts toward agents with proven cardiovascular benefit, reinforcing revenue resilience across the Malaysia oral anti-diabetic drug market.

Complete Report Scope:

• By Drug Class
  • Biguanides
  • Sulfonylureas
  • Meglitinides
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • SGLT-2 Inhibitors
  • Others
• By Age Group
  • Adults
  • Pediatric
  • Geriatric
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

1. Merck
2. Novo Nordisk
3. AstraZeneca
4. Boehringer Ingelheim
5. Takeda Pharmaceuticals
6. Eli Lilly and Company
7. Pfizer
8. Johnson & Johnson
9. Bristol-Myers Squibb
10. Novartis
11. Sanofi
12. Astellas Pharma
13. Duopharma Biotech Berhad
14. Sunward Pharmaceutical Sdn Bhd
15. Hovid Berhad
16. Glenmark Pharmaceuticals
17. Mylan NV (Viatris)
18. Lupin
19. Cipla
20. Bayer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Prevalence Of Type-2 Diabetes In Urban Malaysia
  • 4.2.2 Expansion Of The Private Health-Insurance Pool
  • 4.2.3 Rapid Uptake Of SGLT-2 & DPP-4 Inhibitors Post-NEML 2024 Update
  • 4.2.4 Government-Led Mysihat Medication-Adherence Programmes
  • 4.2.5 Centralised Pharmaniaga Tenders Squeezing Retail Prices
  • 4.2.6 Growth Of E-Pharmacy Platforms Enhancing Last-Mile Reach
• 4.3 Market Restraints
  • 4.3.1 Intensifying Generic Competition After Key Patent Expiries
  • 4.3.2 High Out-Of-Pocket Cost For Latest Agents Despite Reimbursement
  • 4.3.3 Halal Certification Gaps Limiting Acceptance Of Some Branded Generics
  • 4.3.4 Logistics Hurdles To East Malaysia Causing Stock-Out Risk
• 4.4 Regulatory Landscape
• 4.5 Porters Five Forces Analysis
  • 4.5.1 Bargaining Power of Suppliers
  • 4.5.2 Bargaining Power of Consumers
  • 4.5.3 Threat of New Entrants
  • 4.5.4 Threat of Substitute Products and Services
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Biguanides
  • 5.1.2 Sulfonylureas
  • 5.1.3 Meglitinides
  • 5.1.4 Thiazolidinediones
  • 5.1.5 Alpha-Glucosidase Inhibitors
  • 5.1.6 DPP-4 Inhibitors
  • 5.1.7 SGLT-2 Inhibitors
  • 5.1.8 Others
• 5.2 By Age Group
  • 5.2.1 Adults
  • 5.2.2 Pediatric
  • 5.2.3 Geriatric
• 5.3 By Diabetes Type
  • 5.3.1 Type 1 Diabetes
  • 5.3.2 Type 2 Diabetes
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Merck & Co.
  • 6.3.2 Novo Nordisk A/S
  • 6.3.3 AstraZeneca plc
  • 6.3.4 Boehringer Ingelheim
  • 6.3.5 Takeda Pharmaceutical
  • 6.3.6 Eli Lilly and Company
  • 6.3.7 Pfizer Inc.
  • 6.3.8 Johnson and Johnson
  • 6.3.9 Bristol Myers Squibb
  • 6.3.10 Novartis AG
  • 6.3.11 Sanofi S.A.
  • 6.3.12 Astellas Pharma
  • 6.3.13 Duopharma Biotech Berhad
  • 6.3.14 Sunward Pharmaceutical Sdn Bhd
  • 6.3.15 Hovid Berhad
  • 6.3.16 Glenmark Pharmaceuticals
  • 6.3.17 Mylan NV (Viatris)
  • 6.3.18 Lupin Limited
  • 6.3.19 Cipla Limited
  • 6.3.20 Bayer AG

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment